Results of 2026 Annual General Meeting MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 20 November 2026: In accordance with ASX Listing Rule 3.13.2 and Section 251AA of the Corporations Act 2001 (Cth), the attached information is provided in relation to the resolutions passed by the shareholders of...
Results of Meeting
Filed with ASX · · 4 pages · English
Summary by 6ix AI
The resolutions included the adoption of the remuneration report and the re-election of directors, among others, with all resolutions carried successfully. The document also provides insights into the company's focus on developing therapies for neurodegenerative diseases, particularly Multiple System Atrophy.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Alterity Therapeutics Ltd. on 6ix
Earlier from Alterity Therapeutics
- Chairman's Address to 2026 AGM and CEO Presentation to AGM
- Alterity to Present at Bell Potter Healthcare Conference
- Quarterly Activities/Appendix 4C Cash Flow Report
- Proposed issue of securities - ATH
- Notification regarding unquoted securities - ATH
